Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.
Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical diagnosis and therapeutic decision-making in oncology owing to its enhanced sensitivity in DNA mutation detection, fast-turnaround of samples in comparison to current gold standard methods and the potential...
Main Authors: | Clare M McCourt, Darragh G McArt, Ken Mills, Mark A Catherwood, Perry Maxwell, David J Waugh, Peter Hamilton, Joe M O'Sullivan, Manuel Salto-Tellez |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3724913?pdf=render |
Similar Items
-
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01) -
EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
by: Valérie Costes, et al.
Published: (2013-03-01) -
Pathological Factors Affecting DNA Quality in BRAF, EGFR, and KRAS Gene Molecular Tests
by: Hyon-Goo Yun, et al.
Published: (2020-12-01) -
Systematic quantitative analysis of the comet assay
by: McArt, Darragh Gerrard
Published: (2010) -
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)